For decades, the pursuit of pinpointing genetic causes of disease has operated under a fundamental assumption: if you carry the causative mutation, you will develop the disease. This “necessary and sufficient” model, as it’s often termed, has guided research and clinical practice, leading to the identification of hundreds of mutations linked to conditions ranging from thyroid cancer to inherited retinal degenerations. But a growing body of evidence is challenging this long-held dogma, revealing a far more nuanced relationship between genes and disease than previously understood. The shift isn’t simply about acknowledging the role of lifestyle or environmental factors – it’s about recognizing that even possessing a gene variant once considered definitive isn’t a guarantee of disease onset, and conversely, the absence of that variant doesn’t guarantee protection. This realization is reshaping how we approach genetic counseling, risk assessment, and ultimately, the development of targeted therapies.
The foundation of modern genetics, established by Gregor Mendel’s pea plant experiments in the mid-19th century, laid out the principles of inheritance. While Mendel’s work elegantly demonstrated dominant and recessive traits, the reality of complex genetic interactions extends far beyond simple pairings. Genes don’t operate in isolation; they interact with each other and with the environment, collectively determining an individual’s phenotype – their observable characteristics. The critical concept here is penetrance, the likelihood that a specific genotype will manifest as a specific phenotype. For years, many monogenic diseases – those seemingly caused by a single gene – were believed to have 100% penetrance. Tay-Sachs disease, a devastating neurological disorder, remains a prime example of this, with all individuals inheriting two copies of the mutated gene inevitably developing the condition. However, a wave of recent research, fueled by access to massive genomic databases, is demonstrating that this complete penetrance is far less common than previously thought.
See the original Live Science story for the full account.
Caroline Wright, a professor of genomic medicine at the University of Exeter in England, has been at the forefront of this paradigm shift. Her work, and that of colleagues like Eric Pierce at Mass Eye and Ear and Elizabeth Rossin at Mass General Hospital, highlights a striking discrepancy between findings in clinical samples – patients and their families with a diagnosed disease – and those observed in large, population-level datasets like the U.S. National Institutes of Health’s All of Us cohort and the U.K. Biobank. Wright has identified gene variants that appear to cause disease in nearly all patients studied, yet are present in only a small percentage of the general population. “It kind of challenges our standard dogma,” Wright explains. “In much of single-gene genetics we've often assumed that a particular genetic cause is necessary and sufficient, and everything else is irrelevant. And what we're seeing is that that’s not necessarily true.” This isn’t to say the initial genetic links were incorrect, but rather that they represent only part of the story.
Consider inherited retinal degenerations, a group of conditions leading to vision loss. Researchers previously identified numerous genes associated with these disorders, often observing strong familial links. However, when Pierce and Rossin examined data from the broader population, they found that individuals carrying 167 gene variants thought to cause severe vision loss experienced vision loss less than 30% of the time. This means that 70% of individuals carrying these variants remained unaffected, suggesting the presence of protective factors or modifying genes elsewhere in their genome. This phenomenon isn’t limited to retinal diseases. Similar patterns have emerged in studies of thyroid cancer, brittle bone disease (osteogenesis imperfecta), rare childhood eye cancers, mitochondrial diseases, and even conditions like ovarian insufficiency and certain forms of diabetes. Wright’s unpublished research suggests that variants thought to cause brittle bone disease in almost 100% of clinical cases may only manifest in 21% to 40% of the general population.
The key to unlocking these discrepancies lies in recognizing the “supporting cast” of genes and environmental factors that interact with the primary disease-causing gene. In families with a strong history of a genetic disorder, the supporting cast tends to be similar, obscuring its individual contributions. However, in the diverse genetic landscape of the general population, these secondary genes become more apparent, allowing researchers to investigate their protective or detrimental effects. This is exemplified by research into Huntington’s disease, a neurodegenerative condition. While initially believed to be entirely determined by the number of repeating genetic sequences in the Huntington’s gene, further investigation revealed that individuals carrying a near-threshold number of repeats were at higher risk if they also possessed a specific variant nearby, effectively amplifying the effect of the repeating sequence. This illustrates how seemingly subtle genetic variations can dramatically alter disease risk.
The implications of these findings are profound, particularly as genetic screening becomes increasingly accessible. Parents undergoing in vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD) may make different decisions about which embryos to implant if informed that a genetic variant carries a 20% risk of disease versus a 100% risk. Genetic counseling must evolve to incorporate this nuanced understanding of risk, moving beyond simple “positive” or “negative” assessments. Furthermore, these discoveries have the potential to refine gene therapy approaches. While targeting the primary disease-causing gene remains crucial, understanding the broader genetic context could help identify individuals most likely to respond to treatment and potentially uncover novel therapeutic targets. Anna Murray, a professor of human genetics at the University of Exeter, emphasizes the need for more basic cellular research to understand the complex interplay of genes involved in conditions like ovarian insufficiency, noting that many genes have multiple roles and interactions beyond the affected tissue.
Looking ahead, the next critical step is to move beyond simply identifying modifying genes and environmental factors to understanding how they interact with the primary disease-causing gene. Researchers are launching large-scale global collaborations to investigate these interactions in conditions like retinal disorders and ovarian insufficiency. A crucial question remains: can we develop predictive models that accurately assess an individual’s risk of disease based on their unique genetic profile and environmental exposures? And, perhaps more importantly, can we translate this knowledge into personalized prevention strategies and more effective therapies? The era of simple, single-gene explanations for complex diseases is waning, replaced by a more intricate and challenging, yet ultimately more hopeful, understanding of the genetic landscape.
